Skip to main content

CORRECTION article

Front. Genet., 16 January 2023
Sec. Cancer Genetics and Oncogenomics
Volume 13 - 2022 | https://doi.org/10.3389/fgene.2022.1117731
This article is part of the Research Topic The Role of the Tumor Microenvironment (TME) and relevant Novel Biomarkers in Oncogenesis View all 44 articles

Corrigendum: Transmembrane and coiled-coil domains 3 is a diagnostic biomarker for predicting immune checkpoint blockade efficacy in hepatocellular carcinoma

This article is a correction to:

  1. Transmembrane and coiled-coil domains 3 is a diagnostic biomarker for predicting immune checkpoint blockade efficacy in hepatocellular carcinoma

    1. Read original article
Xinyao Hu&#x;Xinyao Hu1†Hua Zhu,&#x;Hua Zhu2,3†Shi FengShi Feng3Chaoqun WangChaoqun Wang3Yingze Ye Yingze Ye3*Xiaoxing Xiong,, Xiaoxing Xiong1,2,3*
  • 1Cancer Center, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, China
  • 2Department of Neurosurgery, The Affiliated Huzhou Hospital, Zhejiang University School of Medicine (Huzhou Central Hospital), Huzhou, China
  • 3Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China

A Corrigendum on
Transmembrane and coiled-coil domains 3 is a diagnostic biomarker for predicting immune checkpoint blockade efficacy in hepatocellular carcinoma

by Hu X, Zhu H, Feng S, Wang C, Ye Y and Xiong X (2022). Front. Genet. 13:1006357. doi: 10.3389/fgene.2022.1006357

In the published article, there was an error regarding the Affiliation for “Xiaoxing Xiong2,3.” As well as having affiliations 2,3, he should also have “1 Cancer Center, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, China.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: TMCO3, ICB, diagnostics, immune infiltrates, LIHC

Citation: Hu X, Zhu H, Feng S, Wang C, Ye Y and Xiong X (2023) Corrigendum: Transmembrane and coiled-coil domains 3 is a diagnostic biomarker for predicting immune checkpoint blockade efficacy in hepatocellular carcinoma. Front. Genet. 13:1117731. doi: 10.3389/fgene.2022.1117731

Received: 06 December 2022; Accepted: 08 December 2022;
Published: 16 January 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Hu, Zhu, Feng, Wang, Ye and Xiong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Yingze Ye, yeyingze@whu.edu.cn; Xiaoxing Xiong, xiaoxingxiong@whu.edu.cn

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.